|
Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab. |
|
|
No Relationships to Disclose |
|
|
Employment - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
Patents, Royalties, Other Intellectual Property - OncoPlex Diagnostics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
|
|
No Relationships to Disclose |
|
|
Employment - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
Patents, Royalties, Other Intellectual Property - OncoPlex Diagnostics |
|
|
Consulting or Advisory Role - OncoPlex Diagnostics |
Travel, Accommodations, Expenses - OncoPlex Diagnostics |
|
|
No Relationships to Disclose |
|
|
Employment - OncoPlex Diagnostics |
Leadership - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
|
|
Employment - OncoPlex Diagnostics |
Leadership - OncoPlex Diagnostics |
Stock and Other Ownership Interests - OncoPlex Diagnostics |
Patents, Royalties, Other Intellectual Property - OncoPlex Diagnostics |
|
|
No Relationships to Disclose |